Navigation Links
PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
Date:6/2/2009

rmation presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, there can be no assurance that the Company will be awarded a contract under the solicitation under BAA-BARDA-09-34. .Further, significant ad
'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
2. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
3. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
7. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
10. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
(Date:7/31/2014)... , July 31, 2014   Auxilium Pharmaceuticals , ... specialty biopharmaceutical company, today announced that the Company will ... Thursday, August 7, 2014 before the opening of the ... conference call that day at 8:30 a.m. ET to ... 2014. The presentation slides to be used during the ...
(Date:7/31/2014)...  A substantial share of pharmacy and therapeutics ... are included in formularies—say patient support resources from ... Manhattan Research study, Taking the Pulse® Formulary ... P&T committee members in hospitals, managed care organizations ... a high bar for these programs, requiring that ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3
... CHICAGO , June 5 Scientists from ... presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used ... slightly poorer survival rate in post-menopausal women with early stage ... findings were announced today at the 2010 American Society of ...
... BARBARA, Calif. , June 4 Abviva, Inc. (Pink ... of breast cancer related applications of Mammastatin, today provided further details ...   , , , ... appoints W.T. Uniack & Co. as its independent auditor. ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4Abviva Engages W.T. Uniack & Co. As Independent Auditor 2
(Date:7/31/2014)... July 31, 2014 In today’s world, a ... to get. Snoring and sleep apnea (a medical problem where ... and their bed partners of the rest they need to ... the population snores and 20 million people in the United ... been diagnosed and treated; and of those treated, many cannot ...
(Date:7/31/2014)... NV (PRWEB) July 31, 2014 Niche Profit ... Adam Short that is designed to provide a blueprint for ... the attention of Shane Michaels, prompting an investigative review. ... , “What really speaks volumes about the success of the ... and strategies included in it have stayed effective even through ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Hook Your Ex, a ... get ex’s to feel emotionally hungry for their partner, to the ... chance. This little trick has been taught to hundreds of ... a quick Hook Your Ex review , Shane Michaels agrees ... suffering pain from a breakup a second chance at getting back ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Cosmetic ... benefit both patients and doctors. Doctors will be able ... to leave reviews , which guarantees their authenticity. ... options on the site to receive information that has ... This unprecedented validation system allows Cosmetic Town to filter ...
(Date:7/31/2014)... Farmington, NY (PRWEB) July 31, 2014 ... restaurants incorporating Pioneer Millworks’ reclaimed wood to create ... the environment. Their newest location features reclaimed ... the restaurant, with custom selected mixed softwoods flowing ... trusses crafted by Pioneer Millworks’ sister company ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Hook Your Ex Review by Shane Michaels Exposes Steve Pratt And His New Method For Getting Back With The Ex 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2Health News:Popular Tavern Restaurant Features Pioneer Millworks’ Reclaimed Wood in New Locations 2
... have raised questions regarding differences in quality of care ... In fact, a growing body of health services research ... the weekend and increased mortality. This "weekend effect" has ... specific intensive treatments and procedures. , Two recent studies ...
... the March 1 issue of the journal SLEEP ... promising model for addressing adolescent sleep problems, given ... healthy sleep knowledge and practice. , The program, ... period, had a high retention rate of 83 percent ...
... green vegetables such as broccoli and cabbage could ... cancer researchers. Tests on mice suggest that these ... safely and effectively than conventional therapy. , "There ... that trigger melanoma," said Gavin Robertson, associate professor ...
... Bethesda, MD (March 1, 2009) Although the ... is well established, studies investigating the association between ... (BE) and esophageal adenocarcinoma (EAC) have reported inconsistent ... of alcohol on BE, especially related to alcohol ...
... Brian Schweitzer, Chair of the Democratic Governors Association, today ... Gov. Kathleen Sebelius as Secretary of Health and Human ... Kathleen Sebelius is an excellent choice to lead the ... our health care system, Governor Sebelius will bring a ...
... precautions should be abandoned, experts note , , SATURDAY, ... trip is as important as packing the right clothes. ... doesn,t mean it,s safe," Laura Gonzalez, a nurse with The ... said in a news release issued by the school. "You ...
Cached Medicine News:Health News:Patients with GI bleeding admitted on the weekend have higher death rate 2Health News:Patients with GI bleeding admitted on the weekend have higher death rate 3Health News:School-based intervention is a promising model for improving adolescent sleep habits 2Health News:School-based intervention is a promising model for improving adolescent sleep habits 3Health News:Vegetable-based drug could inhibit melanoma 2Health News:Alcohol types and socioeconomic status are associated with Barrett's esophagus risk 2Health News:Alcohol types and socioeconomic status are associated with Barrett's esophagus risk 3Health News:Travel Safety Can Be a Passport to Good Health 2
Lyphochek Therapeutic Drug Monitoring Control (TDM) contains over 40 analytes with assayed values at three clinically significant levels....
Lyphochek Endocrine Control is a human based product designed to monitor plasma catecholamine testing procedures by HPLC. The analytes are spiked at critical concentrations to cover the dynamic range...
Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
Medicine Products: